– Series A financing co-led by RA Capital, a16z Bio+Health and Nextech Invest, and includes participation from existing investors Emerson Collective Investments (managed by Yosemite), GV (Google Ventures), LoLa Capital Partners and GordonMD Global Investments –
– Stipple Bio is leveraging its Pointillist Platform to identify tumor-specific cell surface epitopes to enable the development of precision oncology medicines with a high therapeutic index –
– Lead candidate STP-100, a novel Antibody Drug Conjugate (ADC) incorporating tumor specific binders designed to avoid on-target/off-tumor toxicity, expected to enter clinical studies in early 2027 –
CAMBRIDGE, Mass., April 06, 2026 (GLOBE NEWSWIRE) — Stipple Bio, Inc., a private biotechnology company harnessing epitope-level precision to create targeted cancer therapies, today announced the close of a $100 million heavily oversubscribed Series A financing. The financing was co-led by RA Capital, a16z Bio+Health and Nextech Invest, and includes participation from existing investors Emerson Collective Investments (managed by Yosemite), GV (Google Ventures), LoLa Capital Partners and GordonMD Global Investments, among others. In conjunction with the financing, Derek DiRocco, PhD and Thilo Schroeder, PhD will join the Stipple Bio Board of Directors which already includes Vineeta Agarwala MD, PhD, Owen Hughes, Jeff Landau and Aaron Ring MD, PhD and Greg Verdine, PhD.
The proceeds from the financing, which should fund the company into 2029, will be used to advance its lead candidate, STP-100, into multiple early-stage clinical studies, and to leverage its Pointillist Platform to identify additional tumor-specific cell surface epitopes enabling the development of additional pipeline candidates with a high therapeutic index.
“We are building upon deep cancer biology expertise to map, target and unlock tumor-specific epitopes which enable us to develop a pipeline of next-generation precision oncology therapeutics,” said Jeff Landau, Chief Executive Officer of Stipple Bio. “This funding positions us to progress STP-100 into the clinic and continue building a broad oncology pipeline. I am extremely pleased to have the support of industry-leading investors who share our enthusiasm towards developing precision and differentiated cancer therapies based on our modality-agnostic Pointillist Platform.”
“Clinical experience with prior antibody drugs has taught us that epitope-level specificity matters. Since the earliest days of Stipple Bio, we’ve been impressed by the team’s vision to move beyond tumor-specific gene expression and to pioneer tumor-specific ‘epitomics’ in precision oncology. We are proud to have supported Stipple Bio since inception and to co-lead this financing as the company advances safer, more effective therapies for patients living with cancer,” said Dr. Agarwala, General Partner at Andreessen Horowitz and lead investor for the a16z Bio+Health Fund.